Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Survival rates of Spectron clarified:

This article was originally published in Clinica

Executive Summary

Smith & Nephew has pointed out that reference to Spectron's performance in the Swedish study on hip revisions reported in Clinica No 706, p 5 relates to the metal-backed implant. The current version of the Spectron hip - the All-Poly - had the highest survival rate of all hips included in the study. The nine-year survival rate for the All-Poly version was 99.2% (in 939 patients) compared with 87.9% for the metal-backed version (1,362 patients).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT088390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel